White Pine Capital’s Aevi Genomic Medicine Inc GNMX Stock Holding History

White Pine Capital’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20,000	Closed	-$27K	–	230
2017 Q2	$27K	Hold	20,000	–	–	0.01%	217
2017 Q1	$37K	Hold	20,000	–	–	0.02%	210
2016 Q4	$104K	Hold	20,000	–	–	0.04%	201
2016 Q3	$111K	Hold	20,000	–	–	0.05%	204
2016 Q2	$111K	Hold	20,000	–	–	0.05%	204
2016 Q1	$88K	Hold	20,000	–	–	0.04%	203
2015 Q4	$120K	Hold	20,000	–	–	0.05%	197
2015 Q3	$156K	Hold	20,000	–	–	0.07%	203
2015 Q2	$123K	Hold	20,000	–	–	0.05%	202
2015 Q1	$161K	Hold	20,000	–	–	0.07%	199
2014 Q4	$101K	Hold	20,000	–	–	0.03%	208
2014 Q3	$104K	Hold	20,000	–	–	0.04%	213
2014 Q2	$155K	Hold	20,000	–	–	0.05%	203
2014 Q1	$140K	Hold	20,000	–	–	0.05%	215
2013 Q4	$120K	Hold	20,000	–	–	0.04%	226
2013 Q3	$156K	Hold	20,000	–	–	0.05%	221
2013 Q2	$76K	Buy	+20,000	New	+$82K	0.03%	226

Other funds holding GNMX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

NCMW

Northern Capital Management (Wisconsin) Madison, Wisconsin $373M AUM 11.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

White Pine Capital's GNMX Position: Q3 2017 in Review

White Pine Capital sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2017, closing a stake of 20,000 shares — an estimated $27K sold.

White Pine Capital first reported a position in GNMX in Q2 2013 and held it in 17 quarters. The position peaked at $161K in Q1 2015. 49 funds tracked by Wall St. Rank hold GNMX as of Q3 2017.

White Pine Capital reported no remaining Aevi Genomic Medicine Inc position as of Q3 2017 after selling out during the quarter.
White Pine Capital sold 20,000 Aevi Genomic Medicine Inc shares in Q3 2017, an estimated $27K.
White Pine Capital first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 17 quarters.
White Pine Capital's Aevi Genomic Medicine Inc position peaked at $161K in Q1 2015.
49 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2017.

Based on White Pine Capital's 13F filing for Q3 2017, filed 13 Nov 2017.